Limited evidence to support its use, but fairly commonly used for insomnia in clinical practice.

Consider sertraline a first-line agent for kids with depression and anxiety disorders.

Minimal efficacy data in pediatric patients, combined with the likelihood that adolescents may not follow diet restrictions, relegate this medication to third-line status. 

Lack of efficacy, side effects, and discontinuation symptoms make paroxetine a poor choice for children with depression.

Second- or third-line agent due to limited data. 

Fluvoxamine was the first SSRI approved for OCD in children as young as 8.

Consider fluoxetine a first-line agent for children and adolescents with depression and anxiety disorders.

Although only one of three randomized controlled trials led to FDA approval in adolescents, escitalopram may still be considered a first-line agent due to the limited number of effective options—particularly for adolescents with depression and anxiety disorders.

Mixed data and potentially more side effects than SSRIs (particularly increases in blood pressure and pulse) relegate duloxetine to a second-line option for pediatric depression.

There are no clear advantages to using desvenlafaxine over other agents, particularly venlafaxine XR. Given minimal data in children, venlafaxine is generally preferred when choosing an SNRI.